Coronavirus guidance

If you think you may have symptoms of Coronavirus >, follow the national guidance and self-isolate for 10 days. Please see our information on Coronavirus and changes to our normal services >. If you, or a member of your family has tested positive for Coronavirus, please find resources to aid your/their recovery on our Coronavirus - Supporting your recovery > page.

Study findings

This section covers the ongoing investigations and findings of the ARID study.


Current developments

The ARID Study Team are collaborating with colleagues at the University of Leeds and Randox.  We are investigating potential biomarkers linked to the risk of AKI.  This process involves testing samples using novel tests.  The data is then analysed to establish whether the results are statistically significant.

The test methods being used are proven to give consistent results under development conditions.  However they are not currently available for general use.  The research will be used to identify biomarkers that may be suitable for use in future routine testing.

A lot of work has already taken place.  First a representative sub-group had to be identified.  The samples for this sub-group were then tested to establish whether the results are likely to be significant for the entire study population.  This stage has been completed and is promising!

In the ARID Main Study there are around 1,000 participants. Testing of the samples for multiple novel biomarkers has been time consuming. Once the sample testing was completed, the statistical data had to be evaluated to establish whether the findings revealed any new information. This work is in its final stages and we hope to be able to communicate this to the medical world in 2020.

Biomarkers are proteins in the blood and urine

Year 3 Key Findings

*Information coming soon*

Participant feedback meetings

All the participants currently active in both the ARID Pilot and ARID Main Studies we invited to attend presentations about the study progress and findings.  In all over 1,100 letters were sent out.  We were delighted with the response and quickly arranged for a second session.

The meetings were held at Riverside Court, Pride Park, Derby, in May and June 2017.  There were three presentations about the study organisation; findings to date and pharmacy implications of AKI. The talks were followed by a Q&A session which continued as refreshments were provided.